Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD

• Status: Unknown status
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess genetic features and intraocular cytokine profiles of non-responders to anti-VEGF treatment of exudative age-related macular degeneration. Also to assess necessity and frequency of pro re nate medical re-treatment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Cologne
• Treatments: Bevacizumab; Ranibizumab

Criteria

Inclusion Criteria:

• active subfoveal CNV related to exudative age-related macular degeneration (all subforms)

• age > 60 years

• visual acuity > 20/400

• no previous treatment for AMD

Exclusion Criteria:

• any previous AMD therapy

• other CNV types (myopic, parapapillary)

• contraindication for ranibizumab treatment

• prior study participation for AMD

• pregnancy / premenopausal women